证券代码：600535 证券简称：天士力 编号：临 2025-054 号 天士力医药集团股份有限公司 关于公司 2025 年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、报告期内分行业经营数据 单位：元 币种：人民币 | 行业 | | 主营业务收入 | | | | | 主营业务成本 | | | 毛利率（%） | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 2025 年 1-6 月 | 2024 年 | 1-6 月 | 增长率 （%） | 2025 年 1-6 | 月 | 2024 年 1-6 月 | 增长率 （%） | 2025 年 1-6 月 | 2024 年 1-6 月 | 增长率 | | 医药工业 | 3,878,791,353.56 | | 3,896,198,306.32 | -0.45 | 1,120,740,357.95 | | 1,098,534,686.76 ...

Core Insights - The event highlighted the "2024 Annual Top 100 Enterprises in China's Pharmaceutical Industry," where Huabang Health (002004) was recognized as a leading pharmaceutical company again [1] - The ranking reflects the company's strong innovation drive and professional promotion capabilities within the pharmaceutical industry [1] Company Performance - Huabang Health has consistently focused on the health industry, enhancing its R&D investment, product quality control, and market channel expansion [1] - The company has improved its ranking since first being listed in 2020, showcasing its robust overall strength and industry leadership [1] Financial and Operational Highlights - In 2024, Huabang Health's medical business revenue showed steady growth, with bed utilization rates also improving [1] - The company placed significant emphasis on pharmaceutical R&D, achieving several milestones: four formulation products received market approval, one formulation product passed consistency evaluation, six raw material drug varieties and pharmaceutical excipients obtained A certification, and five raw material drug varieties received international certification [1] Product Development - Huabang Health is actively expanding into the dermatological product sector, launching two new functional skincare products to enhance its skin health product matrix [1] - The company aims to develop a comprehensive industry chain that integrates raw materials, formulations, functional skincare products, skin health management, and medical services [1]

Group 1 - The core point of the article is that Wohuah Pharmaceutical announced a plan for a significant share reduction by a board member, which may impact investor sentiment and stock performance [1] - Zhang Ge, a board member and secretary, plans to reduce his holdings by up to approximately 2.51 million shares, representing about 1.74% of the company's total share capital [1] - As of the report, Wohuah Pharmaceutical has a market capitalization of 4.2 billion yuan [1] Group 2 - For the first half of 2025, Wohuah Pharmaceutical's revenue composition is entirely from the pharmaceutical industry, with a 100% contribution [1]

珍宝岛（SH 603567，收盘价：12.97元）8月11日晚间发布公告称，为满足全资子公司黑龙江珍宝岛医 药贸易有限公司（以下简称黑医贸）的银行融资需要，公司拟为黑医贸的银行融资提供总计不超过人民 币4亿元连带责任担保，担保额度的有效期为自公司2025年第二次临时股东会审议通过之日起至公司 2025年年度股东会召开之日止。 （文章来源：每日经济新闻） 2024年1至12月份，珍宝岛的营业收入构成为：医药工业占比87.78%，医药商业占比11.13%，其他业务 占比1.09%。 ...

Group 1 - The core revenue composition of Jianmin Group for the year 2024 is as follows: pharmaceutical industry accounts for 49.83%, pharmaceutical commerce accounts for 49.56%, and other businesses account for 0.6% [1] Group 2 - Jianmin Group announced that its 11th First Board Meeting will be held on July 30, 2025, in Wuhan, Hubei Province, where the agenda includes the election of the company's chairman [3]

Group 1 - The core viewpoint is that the consumer goods industry is a traditional advantage and important livelihood industry in China, significantly contributing to economic growth and foreign trade exports [1] - In the first half of the year, the added value of the consumer goods industry and the value of export delivery accounted for 27.1% and 25.1% of the total industrial output, respectively [1] - The digitalization of light industry enterprises has reached a tool penetration rate of 86.2%, with management digitalization at 82.3%, laying a strong foundation for the mass production of high-value-added products [1] Group 2 - The textile industry has achieved a numerical control rate of key processes at 65.6% and a digital design tool penetration rate of 84.3% as of the first half of the year [2] - The average carbon emission intensity in the textile and apparel industry has decreased by over 14% in the past two years, indicating ongoing efforts in energy conservation and carbon reduction [2] - The Ministry of Industry and Information Technology has implemented digital transformation plans across various industries, including textiles, light industry, food, and pharmaceuticals, focusing on 82 typical scenarios for intelligent transformation [2]

Core Insights - In 2024, despite ongoing pressure on performance, the top 100 pharmaceutical companies in China are increasing their innovation efforts, with an average R&D expenditure of 830 million yuan, a year-on-year increase of 6.3% [1][6] - The overall revenue of the top 100 companies has declined for three consecutive years, totaling 1,004.97 billion yuan in 2024, indicating challenges from market demand changes and policy adjustments [3][4] - The export value of the top 100 companies has rebounded significantly, with a year-on-year growth of 9.4%, contrasting with the overall industry pressure [4][5] R&D Investment - The average R&D expenditure of the top 100 companies reached a historical high of 830 million yuan in 2024, which is 3.2 times that of ten years ago [6] - 13 companies had an R&D intensity exceeding 15%, with 7 companies surpassing 20% [6] - The R&D investment intensity increased to 8.2%, reflecting a commitment to innovation even amid performance declines [6] Market Dynamics - The pharmaceutical industry is undergoing a structural adjustment from scale growth to quality and efficiency, influenced by localizing foreign companies, innovation transformations of domestic firms, and rapid development in biopharmaceuticals [1][3][10] - The concentration of the industry remains stable, with the top 100 companies accounting for 33.8% of the total revenue, a slight decrease of 1.1 percentage points from the previous year [3][4] Export Performance - The export delivery value of the top 100 companies showed a significant recovery, driven by global market demand, ongoing internationalization strategies, and an upgrade in product structure towards higher value [4][5] - In 2024, Chinese pharmaceutical companies completed over 90 overseas authorizations, with a total transaction value exceeding 50 billion USD [4][5] Innovation and Product Development - A total of 48 innovative drugs were approved in 2024, with 12 coming from the top 100 companies, including several breakthrough therapies [7][8] - The competitive landscape is shifting, with 42 companies achieving growth in both revenue and profit, while 31 companies experienced declines [8][9] Emerging Players - New entrants in the top 10 include Novo Nordisk (China), which entered the list for the first time, and Heng Rui Medicine, which returned with a strong proportion of innovative drug revenue [9][10] - These companies exemplify successful models of localization, innovation transformation, and rapid biopharmaceutical development [10]

Group 1 - The 42nd National Pharmaceutical Industry Information Annual Conference and the 2025 Beijing-Changping Life Science Forum were held in Beijing, focusing on the future development of the pharmaceutical industry through insights, ecosystem building, and resource integration [1][3] - The list of "Top 100 Enterprises in China's Pharmaceutical Industry by Main Business Revenue for 2024" was released, with Sichuan Good Doctor Panzhihua Pharmaceutical Co., Ltd. making the list for the 14th consecutive year, showcasing its sustained comprehensive strength [1][3] - Good Doctor Pharmaceutical Group Co., Ltd. received the "2025 China Pharmaceutical Industry Growth Potential Enterprise Map" award, reflecting industry recognition of its future development potential [1][3] Group 2 - The annual conference has been a significant event since its inception in 1959, witnessing the growth and technological innovation of China's pharmaceutical industry [3] - The conference aims to promote the integration of cutting-edge technological innovation concepts with resources from top pharmaceutical companies, driving innovation and transformation in the industry [3] - The global biopharmaceutical industry is undergoing profound changes, with advancements in AI, synthetic biology, gene editing, and cell therapy accelerating China's pharmaceutical industry's shift towards innovation and high-end development [3] Group 3 - In 2024, Good Doctor Group will invest over 800 million yuan to establish a digital intelligent factory for the production of biological raw materials and large-scale traditional Chinese medicine, enhancing production efficiency and product quality [4] - The construction of the second phase of the digital intelligent factory not only improves the production capacity and level of traditional Chinese medicine but also serves as a model for digital projects, promoting high-quality development in the pharmaceutical production sector in Xichang and Liangshan [4]

Core Insights - The 42nd National Pharmaceutical Industry Information Annual Conference and the 2025 Beijing Changping Life Science Forum were held in Beijing, attracting nearly 100 industry experts and over 600 entrepreneurs and investors, aiming to inject new momentum into the high-quality development of the pharmaceutical and health industry [1] - The Changping District has emerged as a key area for Beijing's international innovation center, with significant achievements in the biopharmaceutical industry, including 27 cell and gene therapy pipelines entering clinical stages, accounting for 5% of the national total [2] - The National Medical Products Administration approved 43 innovative drugs in the first half of 2025, with 40 developed by Chinese companies, highlighting Beijing's strength in pharmaceutical innovation [3] Group 1 - The forum focused on creating a high-end dialogue platform in the life sciences sector, enhancing policy interpretation, industry connections, and investment inspections [1] - The Changping District has established a cluster of 121 innovative enterprises in synthetic biology manufacturing, contributing to a 9.3% annual growth in pharmaceutical and health industry revenue over the past three years, forming a trillion-yuan industry cluster [2] - The Beijing Municipal Government aims to optimize the business environment and introduce supportive policies in areas such as artificial intelligence and healthcare to build a globally influential modern pharmaceutical and health industry cluster [4] Group 2 - The Beijing Future Pharmaceutical Industry Chain Research Institute was inaugurated, focusing on research and development in the pharmaceutical industry chain and supporting key technology collaboration [5] - The forum also marked the launch of significant life science projects in collaboration with major universities, aiming for breakthroughs in biomedicine and high-end equipment [5] - The Ministry of Industry and Information Technology emphasized the rapid growth of innovative pharmaceutical products, with 48 innovative drugs and 65 innovative medical devices approved for market entry [3]

Group 1 - The core viewpoint of the articles highlights the rapid growth and innovation in Beijing's pharmaceutical and healthcare industry, with the city becoming the first in China to surpass a trillion yuan in industry scale [2][3]. - During the 14th Five-Year Plan period, Beijing has launched 12 innovative drugs and approved 54 national innovative medical devices, accounting for nearly one-fourth of the national total [1][3]. - In the first half of 2025, the National Medical Products Administration approved 43 innovative drugs, with 40 developed by Chinese companies, showcasing the strength of local innovation [2][3]. Group 2 - Changping District has signed agreements for 14 major projects, focusing on providing comprehensive services for enterprise development in the pharmaceutical sector [4][5]. - The district has established 57 industrial service platforms, facilitating seamless transitions from incubation to research and development, and clinical trials [4]. - The pharmaceutical health industry in Changping has seen an average annual revenue growth of 9.3% over the past three years, forming a billion-yuan industry cluster [4][5].